Literature DB >> 8496385

Geographical variation in prevalence of hepatitis B virus DNA in HBsAg negative patients.

Y M Lo1, E S Lo, W Z Mehal, M Sampietro, G Fiorelli, G Ronchi, C H Tse, K A Fleming.   

Abstract

AIMS--To study the geographical variation of the prevalence of hepatitis B virus (HBV) DNA in hepatitis B surface antigen (HBsAg) negative subjects. METHODS--A nested polymerase chain reaction (PCR) assay was used to amplify the core region of HBV. The assay was able to detect 10 molecules of a full length HBV plasmid. RESULTS--When applied to HBsAg negative paraffin wax embedded liver samples from Italy, Hong Kong, and the United Kingdom, a geographical variation in the prevalence of HBV-DNA positivity was noted. Two of 18 (11%) of Italian samples and 2/29 (6.9%) of Hong Kong samples were positive for HBV-DNA while none of the 70 cases from the United Kingdom was positive by nested PCR. Contamination by plasmid DNA was excluded using a novel method based on heteroduplex formation. One HBV-DNA positive case had idiopathic chronic active hepatitis, but the diagnoses in the other three HBV-DNA positive cases did not suggest any aetiological connection between HBV-DNA positivity and liver pathology. CONCLUSIONS--HBV-DNA could be detected in the liver tissues of a proportion of HBsAg negative subjects. The prevalence of such cases is related to the endemic rate of a geographical region. The use of HBV PCR on paraffin wax embedded tissues will be valuable for future studies on the molecular epidemiology of HBV.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8496385      PMCID: PMC501208          DOI: 10.1136/jcp.46.4.304

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  23 in total

1.  Heteroduplex formation as a means to exclude contamination in virus detection using PCR.

Authors:  Y M Lo; E S Lo; P Patel; C H Tse; K A Fleming
Journal:  Nucleic Acids Res       Date:  1991-12-11       Impact factor: 16.971

2.  Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia.

Authors:  R K Saiki; S Scharf; F Faloona; K B Mullis; G T Horn; H A Erlich; N Arnheim
Journal:  Science       Date:  1985-12-20       Impact factor: 47.728

3.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

4.  False-positive results and the polymerase chain reaction.

Authors:  Y M Lo; W Z Mehal; K A Fleming
Journal:  Lancet       Date:  1988-09-17       Impact factor: 79.321

5.  Expression of the hepatitis B virus surface, core and E antigen genes by stable rat and mouse cell lines.

Authors:  N M Gough; K Murray
Journal:  J Mol Biol       Date:  1982-11-25       Impact factor: 5.469

6.  Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen.

Authors:  C Bréchot; F Degos; C Lugassy; V Thiers; S Zafrani; D Franco; H Bismuth; C Trépo; J P Benhamou; J Wands
Journal:  N Engl J Med       Date:  1985-01-31       Impact factor: 91.245

7.  Lack of hepatitis B virus DNA sequences in sera from patients with acute and chronic liver diseases diagnosed as non-A, non-B-hepatitis.

Authors:  J Slusarczyk; G Hess; B G Hansson; K H Meyer Zum Büschenfelde
Journal:  Liver       Date:  1986-12

8.  Hepatitis B virus RNA transcripts and DNA in chronic liver disease.

Authors:  O Yokosuka; M Omata; F Imazeki; Y Ito; K Okuda
Journal:  N Engl J Med       Date:  1986-11-06       Impact factor: 91.245

9.  Hepatitis B viral nucleotide sequences in non-A, non-B or hepatitis B virus-related chronic liver disease.

Authors:  A Figus; H E Blum; G N Vyas; S De Virgilis; A Cao; M Lippi; E Lai; A Balestrieri
Journal:  Hepatology       Date:  1984 May-Jun       Impact factor: 17.425

10.  Failure to detect nucleic acid homology between some non-A, non-B viruses and hepatitis B virus DNA.

Authors:  M J Fowler; J Monjardino; I V Weller; M Bamber; P Karayiannis; A J Zuckerman; H C Thomas
Journal:  J Med Virol       Date:  1983       Impact factor: 2.327

View more
  8 in total

1.  HLA typing for DR3 and DR4 using artificial restriction fragment length polymorphism PCR from archival DNA.

Authors:  V A Horton; M Bunce; D R Davies; R C Turner; Y M Lo
Journal:  J Clin Pathol       Date:  1995-01       Impact factor: 3.411

Review 2.  Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations.

Authors:  Shunsuke Mori; Shigetoshi Fujiyama
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

Review 3.  Molecular mechanisms underlying occult hepatitis B virus infection.

Authors:  Jasmine Samal; Manish Kandpal; Perumal Vivekanandan
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

4.  Risk of hepatitis B infections in Olympic wrestling.

Authors:  S Bereket-Yücel
Journal:  Br J Sports Med       Date:  2007-03-01       Impact factor: 13.800

5.  Detection of hepatitis B virus surface antigen mutants in paraffin-embedded hepatocellular carcinoma tissues.

Authors:  W N Chen; C J Oon; M C Moh
Journal:  Virus Genes       Date:  2000       Impact factor: 2.332

6.  Molecular characteristics of occult hepatitis B virus from blood donors in southeast China.

Authors:  Quan Yuan; Shan-Hai Ou; Chang-Rong Chen; Sheng-Xiang Ge; Bin Pei; Qing-Rui Chen; Qiang Yan; Yong-Cai Lin; Hong-Ying Ni; Cheng-Hao Huang; Anthony E T Yeo; James W K Shih; Jun Zhang; Ning-Shao Xia
Journal:  J Clin Microbiol       Date:  2009-11-25       Impact factor: 5.948

7.  Pretreatment with restriction enzyme or bovine serum albumin for effective PCR amplification of Epstein-Barr virus DNA in DNA extracted from paraffin-embedded gastric carcinoma tissue.

Authors:  Y Satoh; N Takasaka; Y Hoshikawa; M Osaki; S Ohfuji; H Ito; N Kaibara; T Kurata; T Sairenji
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

8.  Occult hepatitis B among Iranian hepatitis C patients.

Authors:  Ahmad Shavakhi; Babak Norinayer; Fateme Sadat Esteghamat; Mohamad Seghatoleslami; Mahsa Khodadustan; Mohamad Hosein Somi; Mohsen Masoodi; Mohamad Reza Zali
Journal:  J Res Med Sci       Date:  2009-01       Impact factor: 1.852

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.